Media stories about CVS Health (NYSE:CVS) have been trending positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than 6,000 news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CVS Health earned a media sentiment score of 2.83 on their scale. InfoTrie also assigned media stories about the pharmacy operator an news buzz score of 5 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have effected CVS Health’s score:
- Battered health insurers look like a buy – Barron’s (seekingalpha.com)
- CVS Health Corp (CVS) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- CVS Health’s (CVS) Buy Rating Reaffirmed at Cantor Fitzgerald (americanbankingnews.com)
- Best Stock Pick From The 2018 Sohn Conference (Part II) (finance.yahoo.com)
- CVS Health (CVS) Earns Daily Coverage Optimism Score of 2.83 (americanbankingnews.com)
Shares of CVS Health stock opened at $52.63 on Monday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.03 and a quick ratio of 0.65. The stock has a market capitalization of $68.34 billion, a price-to-earnings ratio of 7.43, a PEG ratio of 1.03 and a beta of 0.94. CVS Health has a 52-week low of $51.77 and a 52-week high of $82.15.
CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, February 20th. The pharmacy operator reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $2.07 by $0.07. CVS Health had a negative net margin of 0.31% and a positive return on equity of 17.49%. The firm had revenue of $54.42 billion during the quarter, compared to analyst estimates of $53.78 billion. During the same period in the previous year, the business posted $1.92 earnings per share. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. As a group, research analysts predict that CVS Health will post 6.79 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, May 3rd. Stockholders of record on Tuesday, April 23rd will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 22nd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 3.80%. CVS Health’s dividend payout ratio is presently 28.25%.
CVS has been the subject of a number of recent research reports. Sanford C. Bernstein initiated coverage on shares of CVS Health in a research report on Tuesday, March 12th. They set an “outperform” rating and a $76.00 price target for the company. Morgan Stanley set a $92.00 price target on shares of CVS Health and gave the company a “buy” rating in a research report on Friday, February 22nd. ValuEngine cut shares of CVS Health from a “sell” rating to a “strong sell” rating in a report on Thursday, February 28th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $91.00 target price on shares of CVS Health in a report on Thursday, February 21st. Finally, Citigroup decreased their target price on shares of CVS Health from $94.00 to $68.00 and set a “buy” rating for the company in a report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $79.15.
In related news, Director David W. Dorman purchased 9,600 shares of CVS Health stock in a transaction dated Friday, March 8th. The stock was purchased at an average cost of $52.71 per share, for a total transaction of $506,016.00. Following the completion of the purchase, the director now directly owns 122,302 shares of the company’s stock, valued at approximately $6,446,538.42. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director C David Brown II purchased 10,000 shares of CVS Health stock in a transaction dated Monday, March 11th. The stock was bought at an average price of $53.18 per share, with a total value of $531,800.00. Following the completion of the purchase, the director now directly owns 16,222 shares of the company’s stock, valued at $862,685.96. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 23,600 shares of company stock valued at $1,270,896 and sold 245,671 shares valued at $15,839,966. Insiders own 0.53% of the company’s stock.
CVS Health Company Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Read More: Call Option Volume
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.